RESEARCH TRIANGLE PARK, N.C., March 24, 2022 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug…Original Article
Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food And Drug Administration for Pedmark
